A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia / Ali Ghaleiha en Journal of Clinical Psychopharmacology, Año 2010 - Vol. 30 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 678-682 Título : A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia Tipo de documento: texto impreso Autores: Ali Ghaleiha, Autor ; Ahmad Ali Noorbala, Autor ; Farhad Farnaghi, Autor Fecha de publicación: 2022 Artículo en la página: pp. 678-682 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: 5-HT1A, Buspirona, Esquizofrenia crónica, Síntomas negativos Resumen: The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia. This study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial. Link: ./index.php?lvl=notice_display&id=29415 [artículo] A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia [texto impreso] / Ali Ghaleiha, Autor ; Ahmad Ali Noorbala, Autor ; Farhad Farnaghi, Autor . - 2022 . - pp. 678-682. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 6 (Diciembre) . - pp. 678-682 Palabras clave: 5-HT1A, Buspirona, Esquizofrenia crónica, Síntomas negativos Resumen: The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia. This study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial. Link: ./index.php?lvl=notice_display&id=29415

---

1 (1 - 1 / 1)